HBW Advisory Services LLC grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 144.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,393 shares of the company's stock after acquiring an additional 3,782 shares during the period. HBW Advisory Services LLC's holdings in Johnson & Johnson were worth $1,036,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Innealta Capital LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $27,000. MFA Wealth Advisors LLC acquired a new stake in Johnson & Johnson in the second quarter worth about $43,000. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson during the 4th quarter worth about $44,000. Fairfield Financial Advisors LTD acquired a new position in Johnson & Johnson during the 2nd quarter valued at about $46,000. Finally, Grayhawk Investment Strategies Inc. boosted its stake in shares of Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company's stock valued at $48,000 after purchasing an additional 259 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.
Several equities analysts recently weighed in on the stock. TD Securities cut their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Sanford C. Bernstein raised their price target on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 14th. TD Cowen decreased their target price on Johnson & Johnson from $195.00 to $185.00 and set a "buy" rating for the company in a research report on Thursday, July 18th. Finally, Morgan Stanley upped their price target on Johnson & Johnson from $167.00 to $169.00 and gave the company an "equal weight" rating in a research note on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $173.21.
View Our Latest Research Report on JNJ
Shares of NYSE:JNJ traded down $0.21 during midday trading on Friday, reaching $160.29. 5,331,694 shares of the company were exchanged, compared to its average volume of 7,091,981. The firm has a market cap of $385.77 billion, a PE ratio of 9.99, a P/E/G ratio of 2.69 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The stock has a fifty day simple moving average of $162.60 and a two-hundred day simple moving average of $154.33. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion during the quarter, compared to analysts' expectations of $22.33 billion. During the same period in the prior year, the firm earned $2.80 earnings per share. Johnson & Johnson's revenue for the quarter was up 4.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.09%. Johnson & Johnson's dividend payout ratio (DPR) is presently 30.92%.
In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company's stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company's stock.
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.